Drug Sponsors

TPG Capital to acquire Mediware Information Systems

Friday, December 23, 2016

Mediware Information Systems, a in software for healthcare and human services providers, has announced that TPG Capital, the global private equity fund of alternative asset firm TPG, has entered into a definitive agreement to acquire the company from private equity firm Thoma Bravo. The transaction is expected to close during the first quarter of 2017 and is subject to customary closing conditions. Additional terms of the transaction were not disclosed.

[Read More]

Harbour BioMed acquires Harbour Biomed Antibodies, plans to expand

Tuesday, December 20, 2016

Harbour BioMed, a recently established Shanghai-based company, has acquired Harbour Antibodies for cash and an equity interest in Harbour BioMed to create a new, global oncology-focused biotechnology company. The new company plans to leverage Harbour Antibodies’ patented transgenic mouse platforms to build an internal portfolio of next generation therapeutic antibodies for cancer, expand the range of partnerships and licenses around Harbour’s platforms, and capitalize on the Harbour BioMed management team’s extensive worldwide drug discovery and development expertise.

[Read More]

GSK opens new global vaccines R&D center in Rockville, Maryland

Tuesday, December 13, 2016

GlaxoSmithKline will inaugurate its newest global vaccines research and development (R&D) center in Rockville, Maryland, further strengthening and expanding its vaccines presence in the USA. Up to 200 new jobs will be created at the Rockville facility, with GSK investing over $50 million in the next two years to continue to develop the site with latest state-of-the-art scientific research technology and equipment.

[Read More]

Neurimmune, TVM Capital Life Science launch AL-S Pharma

Tuesday, December 13, 2016

Neurimmune and TVM Capital Life Science’s latest fund, TVM Life Science Ventures VII, has announced their investment in AL-S Pharma, a company based in Schlieren/Zurich, Switzerland. AL-S Pharma will develop, to proof-of-concept, AP-101, a human monoclonal antibody targeting misfolded SOD1 for the treatment of amyotrophic lateral sclerosis (ALS) that was generated and preclinically validated by Neurimmune’s Reverse Translational Medicine platform.

[Read More]

AstraZeneca eliminates 700 positions

Tuesday, December 13, 2016

AstraZeneca will transform its U.S. Commercial business as part of the company’s return to growth strategy. Following the company’s Year End Results announcement this past February, these changes reflect the ongoing focus to further streamline and drive greater efficiency across the entire organization. AstraZeneca continues to face loss of exclusivity impacts from many of its legacy products and works to compete in an ever-changing external environment. By diligently prioritizing, AstraZeneca will continue to successfully launch and commercialize new medicines, meet the needs of our customers and patients, and ultimately help AstraZeneca return to growth.

[Read More]

Report: Higher M&A activity and investor cash expected in 2017

Friday, December 9, 2016

Despite the uncertainty that loomed over the pharma and biotech sectors with unexpected outcomes from both the U.S. presidential election and U.K.’s vote to leave the EU, 2017 may bring renewed energy to the industry with potential for more corporate activity and cash flow. According to EP Vantage, the editorial branch of the market intelligence firm Evaluate, the Trump victory may lead to a slew of business-friendly initiatives, based on the predicted lessening of political scrutiny towards drug pricing. The report shows that although the issue of drug pricing is not going away, 2017 will start with a flush of new confidence for investors, and a possible uptick in mergers and acquisitions.

[Read More]

NovogeneAIT, GIS to establish genome sequencing center in Singapore

Friday, December 9, 2016

Novogene, a commercial provider of genomic services and solutions with cutting edge next-generation sequencing and bioinformatics expertise; AITbiotech, a Singapore biotechnology company; and the Genome Institute of Singapore (GIS) have announced that NovogeneAIT Genomics Singapore (NovogeneAIT) a new joint venture between Novogene and AITbiotech will establish a joint whole genome sequencing (WGS) center at Biopolis, Singapore.

[Read More]